WO1995018606A1 - Curcumin, analogues of curcumin and novel uses thereof - Google Patents

Curcumin, analogues of curcumin and novel uses thereof Download PDF

Info

Publication number
WO1995018606A1
WO1995018606A1 PCT/US1995/000104 US9500104W WO9518606A1 WO 1995018606 A1 WO1995018606 A1 WO 1995018606A1 US 9500104 W US9500104 W US 9500104W WO 9518606 A1 WO9518606 A1 WO 9518606A1
Authority
WO
WIPO (PCT)
Prior art keywords
sep
acid
curcumin
cells
cell
Prior art date
Application number
PCT/US1995/000104
Other languages
English (en)
French (fr)
Other versions
WO1995018606A9 (en
Inventor
Bharat B. Aggarwal
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Priority to AU15585/95A priority Critical patent/AU687509B2/en
Priority to EP95907307A priority patent/EP0738143A1/en
Priority to JP7518587A priority patent/JPH10500657A/ja
Publication of WO1995018606A1 publication Critical patent/WO1995018606A1/en
Publication of WO1995018606A9 publication Critical patent/WO1995018606A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PCT/US1995/000104 1994-01-06 1995-01-05 Curcumin, analogues of curcumin and novel uses thereof WO1995018606A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU15585/95A AU687509B2 (en) 1994-01-06 1995-01-05 Curcumin, analogues of curcumin and novel uses thereof
EP95907307A EP0738143A1 (en) 1994-01-06 1995-01-05 Curcumin, analogues of curcumin and novel uses thereof
JP7518587A JPH10500657A (ja) 1994-01-06 1995-01-05 クルクミン、クルクミン類似体、およびそれらの新しい使用法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17803394A 1994-01-06 1994-01-06
US08/178,033 1994-01-06
US19808894A 1994-02-17 1994-02-17
US08/198,088 1994-02-17

Publications (2)

Publication Number Publication Date
WO1995018606A1 true WO1995018606A1 (en) 1995-07-13
WO1995018606A9 WO1995018606A9 (en) 1997-05-22

Family

ID=26873885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000104 WO1995018606A1 (en) 1994-01-06 1995-01-05 Curcumin, analogues of curcumin and novel uses thereof

Country Status (6)

Country Link
EP (1) EP0738143A1 (un)
JP (1) JPH10500657A (un)
AU (1) AU687509B2 (un)
CA (1) CA2180477A1 (un)
IL (1) IL112205A0 (un)
WO (1) WO1995018606A1 (un)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833629A2 (en) * 1995-06-19 1998-04-08 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
EP1027045A1 (en) * 1997-10-31 2000-08-16 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
WO2000047205A1 (en) * 1999-02-10 2000-08-17 The Trustees Of The University Of Pennsylvania Tyrosine kinase inhibitors and methods of using the same
WO2000061162A1 (en) * 1999-04-09 2000-10-19 Sabinsa Corporation Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (de) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Curcumin-derivate mit gegenüber curcumin verbesserter wasserlöslichkeit und diese enthaltende arzneimittel
DE19821971C2 (de) * 1998-05-18 2003-02-06 Ulti Med Products Deutschland Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
US6653327B2 (en) 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
EP1411959A1 (en) * 2001-07-17 2004-04-28 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
EP1494993A2 (en) * 2002-04-17 2005-01-12 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2006087759A2 (en) * 2005-02-21 2006-08-24 Safi Investment Holding Ag Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
EP1694335A2 (en) * 2003-08-26 2006-08-30 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2006097744A2 (en) * 2005-03-17 2006-09-21 Imperial Innovations Limited Phenol derivatives and their use to modulate pkb activity
WO2007098504A1 (en) * 2006-02-24 2007-08-30 Emory University Prodrugs of curcumin analogs
WO2007112855A1 (en) * 2006-03-30 2007-10-11 Unilever Plc Skin lightening agents, compositions and methods
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2009073050A2 (en) * 2007-07-27 2009-06-11 Research Foundation Of City University Of New York Use of curcumin to block brain tumor formation in vivo
WO2009101263A2 (en) * 2008-02-15 2009-08-20 Novobion Oy Soluble complexes of curcumin
EP2359820A1 (en) 2010-01-29 2011-08-24 Codman & Shurtleff, Inc. Shunt delivery of curcumin for the treatment Alzneimer
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US8647681B2 (en) 2001-06-01 2014-02-11 Mars, Inc. Skin diet
US8648102B2 (en) 2003-12-11 2014-02-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
EP2749552A1 (en) 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
CN105669788A (zh) * 2016-03-18 2016-06-15 昆明理工大学 一种从竹笋中提取活性化合物的方法及其应用
WO2020239948A1 (en) 2019-05-28 2020-12-03 Isanas Ag A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM
US10875841B2 (en) 2018-08-29 2020-12-29 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090681A2 (en) * 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
CN116407527A (zh) * 2023-01-04 2023-07-11 河南科技大学第一附属医院 咖啡酸的应用以及用于预防和治疗口腔鳞癌的药物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3777037A (en) * 1970-09-22 1973-12-04 Us Agriculture Cinnamyl phenols useful as anti-microbial agents
JPS5045660A (un) * 1973-08-25 1975-04-23
JPS57185219A (en) * 1981-05-12 1982-11-15 Chugai Pharmaceut Co Ltd Remedy for cancer
US4421927A (en) * 1980-10-23 1983-12-20 Societe De Recherches Industrielles (S.O.R.I.) New cinnamoyl-cinnamic acid derivative, and its use as pharmaceutical
US4733002A (en) * 1984-05-23 1988-03-22 Green Cross Corporation Lipoxygenase inhibitor
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5238832A (en) * 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
US5288750A (en) * 1988-09-01 1994-02-22 Orion-Yhtyma Oy Substituted β-diketones

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3777037A (en) * 1970-09-22 1973-12-04 Us Agriculture Cinnamyl phenols useful as anti-microbial agents
JPS5045660A (un) * 1973-08-25 1975-04-23
US4421927A (en) * 1980-10-23 1983-12-20 Societe De Recherches Industrielles (S.O.R.I.) New cinnamoyl-cinnamic acid derivative, and its use as pharmaceutical
JPS57185219A (en) * 1981-05-12 1982-11-15 Chugai Pharmaceut Co Ltd Remedy for cancer
US4733002A (en) * 1984-05-23 1988-03-22 Green Cross Corporation Lipoxygenase inhibitor
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5288750A (en) * 1988-09-01 1994-02-22 Orion-Yhtyma Oy Substituted β-diketones
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5238832A (en) * 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEM. ABS., Vol. 107, issued 1987, NISHNO et al., "Antitumor-Promoting Activity of Curcumin, a Major Constituent of the Food Additive Tumeric Yellow", No. 211555. *
CHEM. ABS., Vol. 109, issued 1988, HUANG M.T. et al., "Inhibitory Effect of Curcumin, Chlorogenic Acid, Caffeic Acid, and Ferulic Acid on Tumor Promotion in Mouse Skin by 12-0-Tetradecanoylphorbol-13-Acetate", No. 220060. *
CHEM. ABS., Vol. 110, issued 1989, RAO et al., "Antitumor Acitvity of Phenyl Substituted Cinnamoylmethanes", No. 165550. *
CHEM. ABS., Vol. 113, issued 1990, SOUDAMINI et al., "Cytotoxic and Tumor Reducing Properties of Curcumin", No. 29203. *
CHEM. ABS., Vol. 114, issued 1991, HUANG M.T. et al., II, "Inhibitory Effects of Curcumin on In Vitro Lipoxygenase and Cyclooxygenase Activities in Mouse Epidermis", No. 114763. *
CHEM. ABS., Vol. 115, issued 1991, HUANG T.S. et al., "Suppression of C-Jun/AP-1 Activation by an Inhibitor of Tumor Promotion in Mouse Fibroblast Cells", No. 43302. *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833629A4 (en) * 1995-06-19 1998-09-16 Ontogen Corp ARYL-ACRYLIC ACID DERIVATIVES SUITABLE AS PROTEIN-TYROSINE-PHOSPHATASE INHIBITORS
EP0833629A2 (en) * 1995-06-19 1998-04-08 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
EP1027045A1 (en) * 1997-10-31 2000-08-16 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY
DE19821971C2 (de) * 1998-05-18 2003-02-06 Ulti Med Products Deutschland Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
WO2000047205A1 (en) * 1999-02-10 2000-08-17 The Trustees Of The University Of Pennsylvania Tyrosine kinase inhibitors and methods of using the same
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
WO2000061162A1 (en) * 1999-04-09 2000-10-19 Sabinsa Corporation Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
US6653327B2 (en) 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
EP1196158A1 (en) * 1999-06-30 2002-04-17 Emory University Curcumin and curcuminoid inhibition of angiogenesis
EP1196158A4 (en) * 1999-06-30 2004-05-26 Univ Emory INHIBITION OF ANGIOGENESIS THROUGH THE USE OF CURCUMIN AND CURCUMINOIDS
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (de) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Curcumin-derivate mit gegenüber curcumin verbesserter wasserlöslichkeit und diese enthaltende arzneimittel
US8647681B2 (en) 2001-06-01 2014-02-11 Mars, Inc. Skin diet
EP1411959A4 (en) * 2001-07-17 2007-12-19 Metaproteomics Llc CURCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF THE EXPRESSION AND / OR ACTIVITY OF CYCLOOXYGENASE-2
EP1411959A1 (en) * 2001-07-17 2004-04-28 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US8198323B2 (en) 2002-04-17 2012-06-12 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1494993A2 (en) * 2002-04-17 2005-01-12 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
EP1494993A4 (en) * 2002-04-17 2005-09-14 Univ North Carolina NEW CURCUMINALOGA AND ITS APPLICATIONS
AU2003222087B2 (en) * 2002-04-17 2008-08-21 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
AU2003222087B8 (en) * 2002-04-17 2008-09-04 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
US7709535B2 (en) 2003-03-27 2010-05-04 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1694335A4 (en) * 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS HEMMER AND ITS USES
EP1694335A2 (en) * 2003-08-26 2006-08-30 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US8648102B2 (en) 2003-12-11 2014-02-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US9096499B2 (en) 2003-12-11 2015-08-04 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2006087759A3 (en) * 2005-02-21 2007-02-08 Safi Invest Holding Ag Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
WO2006087759A2 (en) * 2005-02-21 2006-08-24 Safi Investment Holding Ag Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
WO2006097744A3 (en) * 2005-03-17 2007-02-01 Imp Innovations Ltd Phenol derivatives and their use to modulate pkb activity
WO2006097744A2 (en) * 2005-03-17 2006-09-21 Imperial Innovations Limited Phenol derivatives and their use to modulate pkb activity
WO2007098504A1 (en) * 2006-02-24 2007-08-30 Emory University Prodrugs of curcumin analogs
KR101390058B1 (ko) 2006-03-30 2014-04-29 유니레버 엔.브이. 피부 미백제, 조성물 및 방법
WO2007112855A1 (en) * 2006-03-30 2007-10-11 Unilever Plc Skin lightening agents, compositions and methods
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8779151B2 (en) 2006-03-31 2014-07-15 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
EP2749552A1 (en) 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
WO2009073050A2 (en) * 2007-07-27 2009-06-11 Research Foundation Of City University Of New York Use of curcumin to block brain tumor formation in vivo
WO2009073050A3 (en) * 2007-07-27 2009-10-01 Research Foundation Of City University Of New York Use of curcumin to block brain tumor formation in vivo
WO2009101263A2 (en) * 2008-02-15 2009-08-20 Novobion Oy Soluble complexes of curcumin
US8568815B2 (en) 2008-02-15 2013-10-29 Novobion Oy Soluble complexes of curcumin
WO2009101263A3 (en) * 2008-02-15 2009-10-15 Novobion Oy Soluble complexes of curcumin
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US9000179B2 (en) 2008-07-08 2015-04-07 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
EP2359820A1 (en) 2010-01-29 2011-08-24 Codman & Shurtleff, Inc. Shunt delivery of curcumin for the treatment Alzneimer
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
CN105669788A (zh) * 2016-03-18 2016-06-15 昆明理工大学 一种从竹笋中提取活性化合物的方法及其应用
US10875841B2 (en) 2018-08-29 2020-12-29 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US11708350B2 (en) 2018-08-29 2023-07-25 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
WO2020239948A1 (en) 2019-05-28 2020-12-03 Isanas Ag A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM

Also Published As

Publication number Publication date
AU687509B2 (en) 1998-02-26
IL112205A0 (en) 1995-03-15
JPH10500657A (ja) 1998-01-20
CA2180477A1 (en) 1995-07-13
AU1558595A (en) 1995-08-01
EP0738143A1 (en) 1996-10-23

Similar Documents

Publication Publication Date Title
AU687509B2 (en) Curcumin, analogues of curcumin and novel uses thereof
WO1995018606A9 (en) Curcumin, analogues of curcumin and novel uses thereof
Thaloor et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin
Kadekaro et al. α-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes
Kim et al. Methanol extract of Cordyceps pruinosa inhibits in vitro and in vivo inflammatory mediators by suppressing NF-κB activation
Pan et al. Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells
Zhou et al. Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction
Jayakumar et al. Hinokitiol, a natural tropolone derivative, offers neuroprotection from thromboembolic stroke in vivo
Lee et al. α‐Mangostin, a novel dietary xanthone, suppresses TPA‐mediated MMP‐2 and MMP‐9 expressions through the ERK signaling pathway in MCF‐7 human breast adenocarcinoma cells
US5871779A (en) Treatment of arthropathies with vanadate compounds or analogues thereof
CA2377141A1 (en) Curcumin and curcuminoid inhibition of angiogenesis
Hwang et al. 3-Caffeoyl, 4-dihydrocaffeoylquinic acid from Salicornia herbacea inhibits tumor cell invasion by regulating protein kinase C-δ-dependent matrix metalloproteinase-9 expression
Amir et al. Role of COX-2 selective inhibitors for prevention and treatment of cancer
Zhang et al. Suppressing BRD4 exhibits protective effects against vincristine-induced peripheral neuropathy by alleviating inflammation and oxidative stress
Che et al. HO-1: A new potential therapeutic target to combat osteoporosis
US20080300299A1 (en) Application of Eriocalyxin B in the Manufacture of Medicaments For Treating Leukemia
Ostrowski et al. Harnessing oxidative stress for anti-glioma therapy
ZA200407182B (en) Dexanabinol and dexanabinol analogs regulate inflammation releated genes.
Cuzzocrea et al. Superoxide-related signaling cascade mediates nuclear factor-κB activation in acute inflammation
Yang et al. Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
Bedoya et al. The role of parthenolide in intracellular signalling processes: review of current knowledge
Oliver et al. Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis.
Spath et al. Diethyldithiocarbamate inhibits scheduled and unscheduled DNA synthesis of rat thymocytes in vitro and in vivo—dose-effect relationships and mechanisms of action
KR101542774B1 (ko) 리그난 유도체를 함유하는 세라마이드 대사관련 효소에 의해 매개되는 질환의 예방 또는 치료용 조성물
Lee et al. Inhibition of lipopolysaccharide-induced inducible nitric oxide (iNOS) mRNA expression and nitric oxide production by higenamine in murine peritoneal macrophages

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN FI JP KR NO NZ RU US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2180477

Country of ref document: CA

Ref document number: 279068

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995907307

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995907307

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 31,AMENDED CLAIMS,ADDED

WWW Wipo information: withdrawn in national office

Ref document number: 1995907307

Country of ref document: EP